- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02268643
Ultrasound-based Breast Cancer Screening in Chinese Women
October 15, 2014 updated by: Qiang SUN, Peking Union Medical College Hospital
In the present study, the investigators will screen breast cancer of the Chinese women based on ultrasound and aim to compare the risk evaluation model of PUMCH model which was established by our previous work with other risk models.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Early detection of breast cancer through screening has been a common practice in the United States and several European countries for decades.
It is effective in reducing the mortality of breast cancer and improving the postoperative quality of life of patients.
Mammography has been the standard imaging method for the screening, however, our previous study has shown that ultrasound is more sensitive and less expensive than mammography.
In the present study, the investigators will screen breast cancer of the Chinese women based on ultrasound and aim to evaluate the risk model (PUMCH model) which was established by our previous work.
Study Type
Observational
Enrollment (Anticipated)
20000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Chifeng, China
- Recruiting
- Chifeng Baoshan Hospital
-
Contact:
- Yaping Li, MD
-
Principal Investigator:
- Yaping Li, MD
-
Chongqing, China
- Recruiting
- First Affiliated Hospital of Chongqing Medical University
-
Contact:
- Guosheng Ren, MD
-
Principal Investigator:
- Guosheng Ren, MD
-
Mengzi, China
- Recruiting
- First People's Hospital of Honghe State
-
Contact:
- Fengming Xie, MD
-
Principal Investigator:
- Fengming Xie, MD
-
Ordos, China
- Recruiting
- Ordos Central Hospital
-
Contact:
- Zhendong Wang, MD
-
Principal Investigator:
- Zhendong Wang, MD
-
Qingdao, China
- Recruiting
- Qingdao Municipal Hospital
-
Contact:
- Mei Sun, MD
-
Principal Investigator:
- Mei Sun, MD
-
Shenyang, China
- Recruiting
- First Affiliated Hospital of China Medical University
-
Principal Investigator:
- Feng Jin, MD
-
Wulumuqi, China
- Recruiting
- Hospital of Xinjiang Production and Construction Corps
-
Contact:
- Shuanghu Yuan, MD
-
Principal Investigator:
- Shuanghu Yuan, MD
-
Xingtai, China
- Recruiting
- Third Hospital of Xingtai
-
Contact:
- Jingjing Yu, MD
-
Principal Investigator:
- Jingjing Yu, MD
-
Yingshan, China
- Recruiting
- Yingshan Maternal and Child Health Hospital
-
Contact:
- Yue Chen, MD
-
Principal Investigator:
- Yue Chen, MD
-
-
Beijing
-
Beijing, Beijing, China, 100730
- Recruiting
- Peking Union Medical College Hospital
-
Contact:
- Sun Qiang, Doctor
- Phone Number: 86-010-69152701
- Email: sunqiangpumc@163.com
-
Contact:
- Shen Songjie, Doctor
- Phone Number: 86-010-69152701
- Email: pumcssj@163.com
-
Principal Investigator:
- Sun Qiang, Doctor
-
Beijing, Beijing, China
- Recruiting
- Beijing ChaoYang Hospital affiliated to the Capital Medical University
-
Contact:
- Hongchuan Jiang, MD
-
Beijing, Beijing, China
- Recruiting
- Beijing Hospital affiliated to Ministry of Health
-
Contact:
- Bo Li, MD
-
Principal Investigator:
- Bo Li, MD
-
Beijing, Beijing, China
- Recruiting
- First Hospital affiliated to Peking University
-
Contact:
- Yinhua Liu, MD
-
Principal Investigator:
- Yinhua Liu, MD
-
-
Chongqing
-
Chongqing, Chongqing, China
- Recruiting
- Southwest Hospital affiliated to the Third Military Medical University
-
Principal Investigator:
- Jun Jiang, MD
-
-
Shanxi
-
Taiyuan, Shanxi, China
- Recruiting
- ShanXi Traditional Medicine Hospital
-
Contact:
- Yue Shi, MD
-
Principal Investigator:
- Yue Shi, MD
-
-
Tianjin
-
Tianjin, Tianjin, China
- Recruiting
- The Cancer Hospital affiliated to Tianjin Medical University
-
Contact:
- Jin Zhang, MD
-
Principal Investigator:
- Jin Zhang, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
35 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Sampling Method
Non-Probability Sample
Study Population
healthy women without breast-related symptoms
Description
Inclusion Criteria:
- Written informed consent;
- residence from community or working units
Exclusion Criteria:
- pregnancy;
- lactation;
- known metastatic cancer;
- signs or symptoms of breast disease;
- presence of breast implants, breast surgery within prior 12 months;
- had mammography or ultrasound exam within prior 12 months
- males.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
group 1
ultrasound plus clinical breast examination
|
all the participants will be required to fill risk factor questionaires and then be screened with ultrasound plus physical examination every year
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
number of cancer detected in the high-risk group
Time Frame: 3 years
|
3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2014
Primary Completion (Anticipated)
December 1, 2016
Study Completion (Anticipated)
December 1, 2017
Study Registration Dates
First Submitted
September 29, 2014
First Submitted That Met QC Criteria
October 15, 2014
First Posted (Estimate)
October 20, 2014
Study Record Updates
Last Update Posted (Estimate)
October 20, 2014
Last Update Submitted That Met QC Criteria
October 15, 2014
Last Verified
October 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PUMCH-breast-screening 2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Colorado, DenverCompletedStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast CancerUnited States
-
National Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerCanada
-
Mayo ClinicMarker Therapeutics, Inc.CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of Central FloridaFlorida Department of HealthRecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer AwarenessUnited States
Clinical Trials on ultrasound plus clinical breast examination
-
Obafemi Awolowo UniversityPfizerRecruiting
-
International Agency for Research on CancerMalabar Cancer Care Society Kannur, India; Bhabha Atomic Research Centre (BARC)...CompletedCarcinoma in Situ | Breast CancerIndia
-
University Hospital, BrestRecruiting
-
University of ZurichRecruitingBreast Cancer | ImplantsSwitzerland
-
Addis Ababa UniversityMartin-Luther-Universität Halle-Wittenberg; University of the Witwatersrand... and other collaboratorsActive, not recruitingBreast CancerEthiopia
-
University Hospital, Basel, SwitzerlandDePuy SynthesRecruitingArthroscopic Rotator Cuff Repair (ARCR)Switzerland
-
Assistance Publique - Hôpitaux de ParisFondation Paul BennetotRecruitingHeterotopic OssificationFrance
-
Association Pro-arteUniversity Hospital, GrenobleCompleted
-
International Agency for Research on CancerRegional Cancer Centre, Trivandrum, IndiaCompletedBreast Cancer
-
University Hospital, RouenCompleted